风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎

2020-02-20 中国风湿免疫科相关专家小组（统称） Hong Kong Med J. 2020 Feb;26(1):56-65.

DMARDs治疗多关节型JIA附着点炎相关关节炎银屑病关节炎

幼年特发性关节炎（JIA）是儿童最常见的炎症性关节炎，自从引入生物制剂以来，其治疗方案已经扩大。依据最新的信息，来自中国香港的专家小组针对生物类改善病情的抗风湿药(DMARDs)治疗三种JIA亚型，即多关节型JIA(pcJIA)、附着点炎相关关节炎(ERA) 和银屑病关节炎（PsA）的相关内容提出了最新实践共识。

中文标题：

2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎

英文标题：

Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.

发布机构：

中国风湿免疫科相关专家小组（统称）

发布日期：

2020-02-20

简要介绍：

幼年特发性关节炎（JIA）是儿童最常见的炎症性关节炎，自从引入生物制剂以来，其治疗方案已经扩大。依据最新的信息，来自中国香港的专家小组针对生物类改善病情的抗风湿药(DMARDs)治疗三种JIA亚型，即多关节型JIA(pcJIA)、附着点炎相关关节炎(ERA) 和银屑病关节炎（PsA）的相关内容提出了最新实践共识。

 

拓展指南：与关节炎相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎)] GetToolGuiderByIdResponse(projectId=1, id=2dc361c0018e09b3, title=2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎, enTitle=Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement., guiderFrom=Hong Kong Med J. 2020 Feb;26(1):56-65., authorId=null, author=, summary=幼年特发性关节炎（JIA）是儿童最常见的炎症性关节炎，自从引入生物制剂以来，其治疗方案已经扩大。依据最新的信息，来自中国香港的专家小组针对生物类改善病情的抗风湿药(DMARDs)治疗三种JIA亚型，即多关节型JIA(pcJIA)、附着点炎相关关节炎(ERA) 和银屑病关节炎（PsA）的相关内容提出了最新实践共识。 , cover=, journalId=null, articlesId=null, associationId=881, associationName=中国风湿免疫科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Feb 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>幼年特发性关节炎（JIA）是儿童最常见的炎症性关节炎，自从引入生物制剂以来，其治疗方案已经扩大。依据最新的信息，来自中国香港的专家小组针对生物类改善病情的抗风湿药(DMARDs)治疗三种JIA亚型，即多关节型JIA(pcJIA)、附着点炎相关关节炎(ERA) 和银屑病关节炎（PsA）的相关内容提出了最新实践共识。 </P> <P> </P>拓展指南：<strong>与<font color=red>关节炎</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=72aa51c0018e0769" title="全身型幼年特发性关节炎诊断与治疗中国专家共识（2019年版）" target=_blank>全身型幼年特发性关节炎诊断与治疗中国专家共识（2019年版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=142071c001860069" title="2019 EULAR建议：应用合成或生物类改善病情抗风湿药治疗类风湿性关节炎" target=_blank>2019 EULAR建议：应用合成或生物类改善病情抗风湿药治疗类风湿性关节炎</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=0f3cd1c001855313" title="2020 ILAR建议：资源贫乏地区银屑病关节炎的管理" target=_blank>2020 ILAR建议：资源贫乏地区银屑病关节炎的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a156c1c00185a0c7" title="2019 ACR/AF指南：手、髋和膝关节骨关节炎的管理" target=_blank>2019 ACR/AF指南：手、髋和膝关节骨关节炎的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d20f51c0018a316c" title="2019 台湾临床实践建议：影像学检查在中轴型脊柱关节炎的诊断和管理中的应用" target=_blank>2019 台湾临床实践建议：影像学检查在中轴型脊柱关节炎的诊断和管理中的应用</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E5%85%B3%E8%8A%82%E7%82%8E" target=_blank>有关关节炎更多指南</a></ul>, tagList=[TagDto(tagId=65271, tagName=DMARDs), TagDto(tagId=100136, tagName=治疗多关节型JIA), TagDto(tagId=100137, tagName=附着点炎相关关节炎), TagDto(tagId=1613, tagName=银屑病关节炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3934, appHits=220, showAppHits=15, pcHits=1322, showPcHits=3325, likes=9, shares=24, comments=5, approvalStatus=1, publishedTime=Sat Feb 29 23:05:56 CST 2020, publishedTimeString=2020-02-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Feb 29 23:05:56 CST 2020, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 14:18:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎)])
2020 香港共识声明：生物类改善病情的抗风湿药(DMARDs)治疗多关节型JIA、附着点炎相关关节炎和银屑病关节炎
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1078712, encodeId=726a10e87122d, content=好！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:11:18 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978944, encodeId=d28c9e8944f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3505535937, createdName=ms1000000783007837, createdTime=Fri Jul 02 11:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961771, encodeId=a7c1961e711f, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Apr 30 11:12:52 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901959, encodeId=c030901959c5, content=如何赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3765131140, createdName=146576f8m79暂无昵称, createdTime=Tue Nov 24 21:43:32 CST 2020, time=2020-11-24, status=1, ipAttribution=)]
    2021-12-10 yingxin0502

    好！！！！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1078712, encodeId=726a10e87122d, content=好！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:11:18 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978944, encodeId=d28c9e8944f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3505535937, createdName=ms1000000783007837, createdTime=Fri Jul 02 11:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961771, encodeId=a7c1961e711f, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Apr 30 11:12:52 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901959, encodeId=c030901959c5, content=如何赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3765131140, createdName=146576f8m79暂无昵称, createdTime=Tue Nov 24 21:43:32 CST 2020, time=2020-11-24, status=1, ipAttribution=)]
    2021-07-02 ms1000000783007837

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1078712, encodeId=726a10e87122d, content=好！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:11:18 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978944, encodeId=d28c9e8944f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3505535937, createdName=ms1000000783007837, createdTime=Fri Jul 02 11:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961771, encodeId=a7c1961e711f, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Apr 30 11:12:52 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901959, encodeId=c030901959c5, content=如何赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3765131140, createdName=146576f8m79暂无昵称, createdTime=Tue Nov 24 21:43:32 CST 2020, time=2020-11-24, status=1, ipAttribution=)]
    2021-04-30 小强的姣宝

    学习到了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1078712, encodeId=726a10e87122d, content=好！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:11:18 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978944, encodeId=d28c9e8944f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3505535937, createdName=ms1000000783007837, createdTime=Fri Jul 02 11:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961771, encodeId=a7c1961e711f, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Apr 30 11:12:52 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901959, encodeId=c030901959c5, content=如何赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3765131140, createdName=146576f8m79暂无昵称, createdTime=Tue Nov 24 21:43:32 CST 2020, time=2020-11-24, status=1, ipAttribution=)]
    2020-11-24 146576f8m79暂无昵称

    如何赚积分

    0